



ORIGINAL ARTICLE

Long-term outcomes after radiofrequency catheter ablation of the atrioventricular node: The experience of a Portuguese tertiary center



Ana Mosalina Manuel^{a,*}, João Almeida^a, Paulo Fonseca^a, Joel Monteiro^b, Cláudio Guerreiro^a, Ana Raquel Barbosa^a, Pedro Teixeira^a, José Ribeiro^a, Elisabeth Santos^a, Filipa Rosas^a, José Ribeiro^a, Adelaide Dias^a, Daniel Caeiro^a, Olga Sousa^a, Madalena Teixeira^a, Marco Oliveira^a, Helena Gonçalves^a, João Primo^a, Pedro Braga^a

^a Cardiology Department, Vila Nova de Gaia/Espinho Hospital Centre, Porto, Portugal

^b Cardiology Department, Funchal Central Hospital, Madeira, Portugal

Received 24 December 2019; accepted 5 May 2020

KEYWORDS

Supraventricular arrhythmias;
Atrioventricular node ablation;
Heart failure

Abstract

Introduction: In patients with supraventricular arrhythmias and high ventricular rate, unresponsive to rate and rhythm control therapy or catheter ablation, atrioventricular (AV) node ablation may be performed.

Objectives: To assess long-term outcomes after AV node ablation and to analyze predictors of adverse events.

Methods: We performed a detailed retrospective analysis of all patients who underwent AV node ablation between February 1997 and February 2019, in a single Portuguese tertiary center.

Results: A total of 123 patients, mean age 69 ± 9 years and 52% male, underwent AV node ablation. Most of them presented atrial fibrillation at baseline (65%). During a median follow-up of 8.5 years (interquartile range 3.8–11.8), patients improved heart failure (HF) functional class (NYHA class III–IV 46% versus 13%, $p=0.001$), and there were reductions in hospitalizations due to HF (0.98 ± 1.3 versus 0.28 ± 0.8 , $p=0.001$) and emergency department (ED) visits (1.1 ± 1 versus 0.17 ± 0.7 , $p=0.0001$). There were no device-related complications. Despite permanent pacemaker stimulation, left ventricular ejection fraction did not worsen ($47 \pm 13\%$ vs. 47 ± 12 , $p=0.63$). Twenty-eight patients died (23%). The number of ED visits due to HF before AV node ablation was an independent predictor of the composite adverse outcome (OR 1.8, 95% CI 1.24–2.61, $p=0.002$).

* Corresponding author.

E-mail address: mosalina@live.com.pt (A.M. Manuel).

Conclusions: Despite pacemaker dependency, the clinical benefit of AV node ablation persisted at long-term follow-up. The number of ED visits due to HF before AV node ablation was an independent predictor of the composite adverse outcome. AV node ablation should probably be considered earlier in the treatment of patients with supraventricular arrhythmias and HF, especially in cases that are unsuitable for selective ablation of the specific arrhythmia.

© 2020 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALAVRAS-CHAVE

Disritmias
supraventriculares;
Ablação do nódulo
auriculoventricular;
Insuficiência cardíaca

Desfechos a longo prazo após ablação do nódulo auriculoventricular por radiofrequência: a experiência de um centro terciário português

Resumo

Introdução: Nos doentes com disritmias supraventriculares e frequência ventricular elevada, irresponsivos à terapêutica para controlo da frequência e do ritmo, ou à ablação por catéter, a ablação do nódulo auriculoventricular (ANAV) pode ser realizada.

Objetivos: Avaliar os resultados em longo prazo após a ANAV e analisar preditores de eventos adversos.

Métodos: Análise retrospectiva detalhada, dos doentes submetidos à ANAV entre fevereiro 1997 e fevereiro 2019, num centro terciário português.

Resultados: Foram submetidos 123 doentes à ANAV: idade média 69 ± 9 anos e 52% homens. A maioria apresentou fibrilhação auricular (65%). Num período mediano de seguimento de 8,5 anos (intervalo interquartil 3,8-11,8), houve melhoria da classe funcional de insuficiência cardíaca (IC) (classe NYHA III-IV 46% versus 13%, $p = 0,001$) e redução dos internamentos por IC ($0,98 \pm 1,3$ versus $0,28 \pm 0,8$, $p=0,001$), redução dos recursos ao serviço de urgência (SU) ($1,1 \pm 1$ versus $0,17 \pm 0,7$, $p=0,0001$). Não houve complicações relacionadas ao dispositivo. Apesar da estimulação permanente de *pacemaker*, a FEVE não agravou ($47\% \pm 13$ versus $47\% \pm 12$, $p=0,63$). Faleceram 28 doentes (23%). O número de recursos ao SU por IC antes do procedimento foi preditor independente do composto de eventos adversos (OR 1,8, IC95%, 24-2,61, $p=0,002$). **Conclusões:** Apesar da dependência de *pacemaker*, o benefício clínico da ANAV persistiu a longo prazo. O número de recursos ao SU por IC antes do procedimento foi preditor do composto de eventos adversos. Provavelmente, a ANAV deveria ser considerada mais cedo no tratamento de doentes com disritmias supraventriculares e IC, sobretudo nos casos em que a ablação seletiva da disritmia seja inapropriada.

© 2020 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Supraventricular arrhythmias present a challenge for the management of patients who develop a high ventricular rate and symptoms refractory to medical therapy.

Atrial fibrillation (AF) is the most frequent sustained arrhythmia in clinical practice.^{1,2} AF promotes heart failure (HF) decompensation leading to hospitalizations, and 10-40% of AF patients are hospitalized every year.³ Clinical trials have demonstrated that in about one quarter of these patients, an adequate rate control strategy cannot be achieved.^{4,5} Currently, in patients with supraventricular arrhythmias who are unresponsive or intolerant to pharmacological therapy, rhythm control may be achieved with electrical cardioversion and catheter ablation. Pulmonary veins isolation is a well-established AF treatment, although delayed referral of patients, particularly those with long-standing persistent AF, may reduce its efficacy.⁶ If these

therapies are unsuccessful, atrioventricular (AV) node ablation may be performed.^{1,2}

AV node ablation was first performed in humans in 1981, using high-energy direct current (300-500 J) delivered from a portable defibrillator.⁷ Since its introduction in clinical practice the technique has evolved and nowadays it is mostly performed using radiofrequency ablation followed by permanent pacemaker implantation, a strategy named "ablate and pace".⁸ This strategy has proven efficacy,⁹⁻¹² although patients become pacemaker-dependent and complications may occur, such as ventricular arrhythmias and sudden death.¹³

Most studies have reported symptomatic improvement and favorable safety results after AV node ablation in follow-up periods of around five years.^{14,15} However, long-term right ventricular (RV) stimulation may lead to left ventricular (LV) dysfunction.¹⁶⁻¹⁸ Considering this deleterious consequence, few studies have assessed in detail the

clinical, procedural and echocardiographic outcomes after AV node ablation beyond five years.^{19,20} Therefore, in this study we aimed to assess long-term outcomes after AV node ablation and to analyze clinical predictors of adverse events.

Methods

Study population

We retrospectively reviewed medical records of patients who underwent AV node ablation between February 1997 and February 2019 in a single tertiary center, Vila Nova de Gaia/Espinho Hospital Center, Porto. The local ethics committee approved the study, which was conducted in accordance with the Declaration of Helsinki.

Patients were considered to have refractory supraventricular arrhythmia if they had uncontrolled symptoms after appropriate pharmacological therapies had been tried for periods appropriate to the pharmacokinetics of the agents used, and after exclusion of reversible causes.²¹

Electrocardiographic and echocardiographic assessment

Baseline rhythm was recorded by 12-lead electrocardiogram and 24-hour Holter monitoring. Electrocardiographic analyses were performed according to the recommendations for the standardization and interpretation of the electrocardiogram.²²

Transthoracic echocardiograms were performed before and after the procedure. Stored images and reports were analyzed. Quantification of cardiac chambers was performed as recommended by the European Association of Cardiovascular Imaging.²³

Atrioventricular node ablation procedure characteristics

Radiofrequency AV node ablation was performed under fluoroscopic guidance. Following right femoral vein access, the ablation catheter was advanced across the tricuspid valve annulus and was then withdrawn with septal torque until the largest His signal was visualized. Ablation was performed in the atrioventricular node or at the most proximal penetrating part of the His bundle. In the event of failure of right-side ablation attempts, AV node ablation was performed from the left ventricle via a retrograde aortic approach. Dual-chamber pacemakers were implanted in patients with paroxysmal supraventricular arrhythmias while those with permanent arrhythmias, particularly AF, received a single-chamber pacemaker.

Immediate success was defined as permanent AV block after catheter ablation. All patients were monitored in the ward for at least 24 hours and a transthoracic echocardiogram was performed before discharge. After AV node ablation, devices were uniformly programmed in VVI mode at 90 beats per minute (bpm) for one month. Devices were systematically interrogated at 24 hours, the first month, the sixth month and biannually thereafter to assess the presence of symptoms, arrhythmias and device parameters.

Outcomes

Primary outcomes were defined as death, unplanned hospitalizations, unplanned emergency department (ED) visits due to heart failure (HF) and NYHA functional class worsening after AV node ablation. The composite outcome was defined as the composite of the primary outcomes.

Statistical analysis

Categorical variables were reported as counts and percentages. Continuous variables were reported as mean \pm standard deviation or median and interquartile range, as appropriate. Normality of distribution of continuous variables was assessed by the Shapiro-Wilk test. Differences were analyzed using the Friedman and Wilcoxon signed-rank tests. All statistical tests were two-sided and a p-value <0.05 was considered statistically significant.

Univariate and multivariate logistic regressions were performed to identify predictors of adverse outcomes after AV node ablation. Statistical analyses were performed using IBM SPSS Statistics version 23.0 (IBM Corp., Armonk, NY).

Results

Patient characteristics

A total of 123 patients, mean age 69 ± 9 years and 52% male, underwent AV node ablation. The clinical characteristics of the study population are shown in [Table 1](#).

AF was the baseline rhythm in most patients (65%) at the time of the procedure. The mean ventricular rate was 114 ± 33 bpm, mean LVEF was 47 ± 13 and 46% of patients were in New York Heart Association (NYHA) functional class III-IV. In the 12 months prior to the procedure, 32% and 44% of patients had at least one unplanned hospitalization and one ED visit due to decompensated HF, respectively.

Procedural characteristics

Detailed information on the procedure and outcomes is shown in [Table 2](#).

Most patients presented severe symptoms or uncontrolled HF due to AF (46%) or atrial flutter (12%). Ten patients (8%) with cardiac resynchronization therapy (CRT) devices presented low biventricular pacing percentage and two patients (2%) with implantable cardioverter-defibrillators (ICDs) received inappropriate shocks related to supraventricular tachycardia.

AV node ablation was successfully performed in all 123 patients, without immediate major adverse events. One patient presented femoral hematoma at discharge and needed prolonged hospitalization for surveillance. Permanent device insertion was performed in the same procedure in 110 patients: 90 with pacemakers (82%), seven with CRT pacemakers (6%), nine with CRT defibrillators (8%) and four with ICDs (4%).

Table 1 Baseline characteristics of the study population (n=123).

Age, years	69±9
Male gender	65 (52%)
Body mass index	27±4
Comorbidities	
NYHA class I-II	67 (54%)
NYHA class III-IV	56 (46%)
Hypertension	52 (42%)
Diabetes	28 (23%)
Obesity	14 (11%)
DCM	31 (25%)
Valvular heart disease	27 (22%)
COPD	4 (3%)
GFR <60 ml/min	24 (20%)
Cerebrovascular disease	8 (7%)
CAD	19 (15%)
Hospitalizations due to HF, mean (previous 12 months)	0.98±1
ED visits due to HF, mean (previous 12 months)	1.1±1
Symptoms	
Palpitations/chest pain	49 (40%)/3 (2%)
Dyspnea/decompensated HF	8 (7%)/53 (43%)
Syncope/dizziness	6 (5%)/2 (2%)
Asymptomatic	2 (2%)
Previous electrical treatment	
Electrical cardioversion	28 (23%)
AF catheter ablation	10 (8%)
Cavotricuspid isthmus ablation	14 (11%)
Medication	
Beta-blockers/amiodarone	71 (58%)/44 (36%)
Other antiarrhythmic agents	22 (18%)
Digoxin	34 (28%)
Anticoagulants/antiplatelet agents	83 (68%)/15 (12%)
ACEIs/ARBs	65 (53%)
Spirolactone/other diuretics	17 (14%)/55 (45%)
Echocardiographic characteristics	
LA diameter, mm	51±7
LVEDD, mm	56±9
Mean LVEF, %	47±13
LVEF <35%	21 (17%)
Electrocardiographic characteristics	
Baseline rhythm	
Sinus	17 (14%)
AF	80 (65%)
Atrial flutter	21 (17%)
Atrial tachycardia	3 (2%)
Pacemaker	2 (2%)
Arrhythmia duration	
Permanent	65 (53%)
Persistent/paroxysmal	21 (17%)/37 (30%)
Heart rate on ECG, bpm	114±33
Heart rate on 24-h Holter, bpm	90±27
QRS duration, ms	117±32
LBBB/RBBB	13 (11%)/2 (2%)
Pacemaker/CRT/ICD	2 (2%)/10 (8%)/1 (1%)

ACEIs: angiotensin-converting enzyme inhibitors; AF: atrial fibrillation; ARBs: angiotensin receptor blockers; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; CRT: cardiac resynchronization therapy device; DCM: dilated cardiomyopathy; ECG: electrocardiogram; ED: emergency department; GFR: glomerular filtration rate (Cockcroft-Gault formula); HF: heart failure; ICD: implantable cardioverter-defibrillator; LA: left atrial; LBBB: left bundle branch block; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association functional class; RBBB: right bundle branch block.

Table 2 Procedure and outcomes.

Indication	
AF/atrial flutter (drug-refractory/uncontrolled HF)	57 (46%)/15 (12%)
Inappropriate ICD shocks	2 (2%)
SND (severely symptomatic or uncontrolled tachycardia)	12 (10%)
Tachycardiomyopathy	27 (22%)
Low biventricular pacing percentage	10 (8%)
Devices implanted before procedure (n=110)	
Pacemaker	90 (82%)
CRT-P	7 (6%)
CRT-D	9 (8%)
ICD	4 (4%)
AV node ablation procedure, elective	123 (100%)
Anterograde approach	123 (100%)
Retrograde approach	13 (11%)
Total procedure time, min	46±18
Fluoroscopy/ablation times, min	8±7/2±2
Immediate success/major complications	123 (100%)/0
Median follow-up, years (IQR)	8.5 (3.8-11.8)
NYHA class I-II	107 (87%)
NYHA class III-IV	16 (13%)
Hospitalizations due to HF (previous 12 months)	0.28±0.8
ED visits due to HF (previous 12 months)	0.17±0.7
QRS under ventricular pacing, ms	173±18
LVEDD, mm	57±9
Mean LVEF, %	47±12
AV node reconnection and repeat procedure	4 (3%)
Major adverse events	12 (10%)
Death	28 (23%)

AF: atrial fibrillation; AV: atrioventricular; CRT-D: cardiac resynchronization therapy defibrillator; CRT-P: cardiac resynchronization therapy pacemaker; ED: emergency department; HF: heart failure; ICD: implantable cardioverter-defibrillator; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association functional class.

Clinical outcomes and echocardiography

During a median follow-up of 8.5 years (IQR 3.8-11.8), there were no device-related complications.

NYHA functional class improved, as shown in [Figure 1](#) (NYHA class III-IV 46% versus 13%, $p = 0.001$), and hospitalizations (0.98 ± 1.3 versus 0.28 ± 0.8 , $p = 0.001$) and ED visits due to HF (1.1 ± 1 versus 0.17 ± 0.7 , $p = 0.0001$) decreased. There were no differences in mean LVEF ($47 \pm 13\%$ vs. $47 \pm 12\%$, $p = 0.63$) or left ventricular end-diastolic diameter (LVEDD) (56 ± 9 vs. 57 ± 9 mm, $p = 0.85$). Four (3%) patients needed a redo procedure. During follow-up 28 patients died (23%).

Clinical predictors of adverse outcomes

Data regarding predictors of adverse outcomes are shown in [Table 3](#). Univariate analysis of predictors of death from any cause after AV node ablation was statistically significant for age (odds ratio [OR] 1.05 per year, 95% confidence interval [CI] 1.00-1.11, $p = 0.029$), number of ED visits due to HF before AV node ablation (OR 1.45, 95% CI 1.06-1.98, $p = 0.019$) and number of hospitalizations (OR 1.52, 95% CI 1.00-2.30, $p = 0.045$).

In multivariate analysis of outcomes, only the number of ED visits due to HF before AV node ablation (OR 1.8, 95% CI 1.24-2.61, $p = 0.002$) was a significant predictor of the composite outcome (C-statistic of the final model 0.012, $p = 0.042$; Hosmer-Lemeshow goodness-of-fit test $p = 0.31$).

Discussion

In this study of consecutive patients undergoing AV node ablation, we observed that: (1) despite pacemaker dependency, the clinical benefit of ablation persisted at long-term follow-up, with reductions in hospitalizations and ED visits due to HF and improvement in NYHA functional class; (2) there were no significant differences in mean LVEF and LVEDD before and after the procedure; (3) the number of ED visits due to HF before AV node ablation was an independent predictor of the composite adverse outcome.

With regard to long-term outcomes, several important studies have assessed the outcomes of AV node ablation and reported clinical improvement and a favorable safety profile. Although these studies had shorter follow-up periods than ours (range 1-4 years), mortality varied between 12% and 41%.²⁴⁻²⁹ After a median follow-up of 8.5 years, mortality in our study (23%) was within this range. Similar mortality




Figure 1 New York Heart Association functional class before and after atrioventricular node ablation. AV: atrioventricular; NYHA: New York Heart Association.

Table 3 Predictors of outcomes after atrioventricular node ablation on univariate and multivariate logistic regression analysis.

	OR	95% CI	p
<i>Univariate analysis of outcomes (death, hospitalizations, ED visits and HF worsening)</i>			
No. of ED visits due to HF before AV node ablation	1.63	1.21-2.20	0.001
No. of hospitalizations due to HF before AV node ablation	1.63	1.11-2.38	0.012
Dilated cardiomyopathy	3.95	1.37-11.3	0.011
ACEIs/ARBs	2.2	0.97-5	0.058
Spironolactone	3.31	1.14-9.59	0.027
Other diuretics	2.75	1.23-6.14	0.013
<i>Multivariate analysis of outcomes (death, hospitalizations, ED visits and HF worsening)</i>			
No. of ED visits due to HF before AV node ablation	1.8	1.24-2.61	0.002
<i>Death from any cause after AV node ablation</i>			
Age	1.05	1.00-1.11	0.029
BMI	0.33	0.12-0.90	0.030
No. of ED visits due to HF before AV node ablation	1.45	1.06-1.98	0.019
No. of hospitalizations due to HF before AV node ablation	1.52	1.00-2.30	0.045

ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; AV: atrioventricular; BMI: body mass index; CI: confidence interval; ED: emergency department; HF: heart failure; OR: odds ratio.

(22%) was reported in a retrospective study of 162 patients with AF who underwent AV node ablation.³⁰

Our results are also in agreement with previous studies that reported improvements in symptoms, reduction of NYHA functional class and hospitalizations after AV node ablation.^{31,32} The reductions in hospitalizations and ED visits due to HF are probably related to improvements in patients' general clinical condition in the context of controlled heart rate, reduced R-R interval variability and improved diastolic filling.³³ In line with these results and although patients became pacemaker-dependent, in our study the clinical benefits after the procedure persisted in long-term follow up.

No significant differences were observed regarding LVEF and LVEDD before and after AV node ablation in the present study. These results are similar to previous reports.²⁹ LV dyssynchrony and dysfunction induced by the abnormal electrical activation pattern of pacing have been documented in other clinical contexts.¹⁶ Particularly after AV node ablation, conflicting results have been observed regarding the impact of ventricular pacing on LV function. In two prospective studies^{34,35} that included AF patients with and without struc-

tural heart disease (29 and 30 patients, follow-up 0.6 and 6.4 years) and in the Ablate and Pace Trial³⁶ (156 patients, follow-up one year), it was observed that LVEF increased after AV node ablation in patients with LVEF <50% at baseline, while those with normal LVEF at baseline had no change during follow-up. Different results were found in observational studies, in which normal LVEF at baseline, assessed by echocardiography and radionuclide ventriculography (12-55 patients, follow-up 0.25-3.8 years), decreased after AV node ablation.³⁷⁻³⁹ Vernooij et al.,⁴⁰ in a study with a similar follow-up period to ours (seven years) but with a smaller population (45 patients), also found that after AV node ablation, RV pacing decreased LVEF in patients with LVEDD <50 mm at baseline. These differences between studies may be related to patient selection criteria, timing and method of LV measurement, sample size and follow-up periods.

Various pacing strategies for patients with AF undergoing AV node ablation have been proposed to overcome the detrimental effects of ventricular pacing on cardiac function.^{41,42} Recent evidence suggests that biventricular pacing could be superior to RV pacing in reducing hospitalizations in these patients.³² Biventricular pacemakers provide coor-

minated activation of the interventricular septum and the lateral wall, resulting in synchronous LV contraction. This technique has proved valuable in improving prognosis in patients with HF and wide QRS complex.⁴³ Previous trials in patients with AF undergoing AV node ablation that compared biventricular pacing with RV pacing^{44,45} and with pharmacological rate-control therapy^{46,47} found that biventricular pacing improved LVEF and reduced hospitalizations and death due to HF. Of note, one trial was conducted exclusively in patients with narrow QRS and favorable results were observed with significantly reduced mortality from any cause after AV node ablation.⁴⁶ In our study, about one fifth of the patients had a cardiac resynchronization therapy device implanted after AV node ablation in accordance with the current recommendations,^{43,48} and there was an overall clinical benefit, irrespective of the implanted device. Beyond conventional biventricular pacing, His bundle pacing is presently a safe alternative to right ventricular pacing after AV node ablation, with improvements in NYHA class and LVEF.^{15,49–52} Based on this evidence,^{32,44,51,53} the guidelines⁵⁴ recommend AV node ablation followed by biventricular or His-bundle pacing in patients with tachycardiomyopathy.

Predictors of clinical outcomes

The number of ED visits due to HF before AV node ablation was a consistent predictor in univariate and multivariate analysis of the adverse outcomes in this study. HF patients who need frequent unplanned medical visits present progressive worsening of functional capacity, quality of life and prognosis.⁵⁵ Consequently, it may be hypothesized that patients with advanced HF, who need multiple acute care services before AV node ablation, present higher rates of adverse outcomes and less clinical benefits after the procedure.

Limitations

The main limitation of this study is its retrospective and nonrandomized nature. The procedure was performed at a single institution and the reproducibility of our results at other laboratories remains to be assessed. Additionally, information regarding causes of death was unavailable in some patients.

Conclusions

AV node ablation is a useful and safe procedure for the treatment of supraventricular arrhythmias, particularly in the context of tachycardiomyopathy.

In our study, despite pacemaker dependency, the clinical benefit of AV node ablation persisted in long-term follow-up, with reductions in hospitalizations and ED visits due to HF and improvement in NYHA functional class. The number of ED visits due to HF before AV node ablation was an independent predictor of adverse outcomes. This intervention should be probably considered earlier in the treatment of patients with supraventricular arrhythmias and HF, especially in cases that are unsuitable for selective ablation of the specific arrhythmia.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* 2019;74:104–32.
2. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J.* 2016;37:2893–962.
3. Goyal P, Almarzooq ZI, Horn EM, et al. Characteristics of hospitalizations for heart failure with preserved ejection fraction. *Am J Med.* 2016;129:635.e15–26.
4. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. *N Engl J Med.* 2010;362:1363–73.
5. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med.* 2002;347:1825–33.
6. Walsh K, Marchlinski F. Catheter ablation for atrial fibrillation: current patient selection and outcomes. *Exp Rev Cardiovasc Ther.* 2018;16:679–92.
7. Scheinman MM, Morady F, Hess DS, et al. Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias. *JAMA.* 1982;248:851–5.
8. Marshall HJ, Griffith MJ. Ablation of the atrioventricular junction: technique, acute and long-term results in 115 consecutive patients. *Europace.* 1999;1:26–9.
9. Lim KT, Davis MJ, Powell A, et al. Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial. *Europace.* 2007;9:498–505.
10. Brignole M, Gianfranchi L, Menozzi C, et al. Prospective, randomized study of atrioventricular ablation and mode-switching, dual chamber pacemaker implantation versus medical therapy in drug-resistant paroxysmal atrial fibrillation. The PAF study. *Paroxysmal Atrial Fibrillation. Europace.* 1999;1:15–9.
11. Gasparini M. Atrioventricular node ablation. *Heart Fail Clin.* 2017;13:193–8.
12. Wasmer K, Hochadel M, Wieneke H, et al. Long-term symptom improvement and patient satisfaction after AV-node ablation vs. pulmonary vein isolation for symptomatic atrial fibrillation: results from the German Ablation Registry. *Clin Res Cardiol.* 2019;108:395–401.
13. Occhetta E, Bortnik M, Dell'era G, et al. Evaluation of pacemaker dependence in patients on ablate and pace therapy for atrial fibrillation. *Europace.* 2007;9:1119–23.
14. Gasparini M, Auricchio A, Regoli F, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. *J Am Coll Cardiol.* 2006;48:734–43.
15. Vijayaraman P, Subzposh FA, Naperkowski A. Atrioventricular node ablation and His bundle pacing. *Europace.* 2017;19 Suppl. 4:iv10–6.
16. Khurwolah MR, Yao J, Kong XQ. Adverse consequences of right ventricular apical pacing and novel strategies to optimize left ventricular systolic and diastolic function. *Curr Cardiol Rev.* 2019;15:145–55.
17. Kutalek SP, Sharma AD, McWilliams MJ, et al. Effect of pacing for soft indications on mortality and heart failure in the dual

- chamber and VVI implantable defibrillator (DAVID) trial. *Pacing Clin Electrophysiol: PACE*. 2008;31:828–37.
18. Zeitler EP, Sanders GD, Singh K, et al. Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis. *Europace*. 2018;20:1621–9.
 19. Carnlof C, Insulander P, Jensen-Urstad M, et al. Atrio-ventricular junction ablation and pacemaker treatment: a comparison between men and women. *Scand Cardiovasc J*. 2018;52:120–6.
 20. Mujovic N, Grujic M, Mrdja S, et al. Long-term follow-up after catheter-ablation of atrioventricular junction and pacemaker implantation in patients with uncontrolled atrial fibrillation and heart failure. *Srp Arh Celok Lek*. 2011;139:591–8.
 21. Brignole M, Gammage M, Jordaens L, et al. Report of a study group on ablate and pace therapy for paroxysmal atrial fibrillation Barcelona Discussion Group. Working Group on Arrhythmias of the European Society of Cardiology. *Europace*. 1999;1:8–13.
 22. Surawicz B, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. *J Am Coll Cardiol*. 2009;53:976–81.
 23. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2015;16:233–70.
 24. Garcia B, Clementy N, Benhenda N, et al. Mortality after atrioventricular nodal radiofrequency catheter ablation with permanent ventricular pacing in atrial fibrillation: outcomes from a controlled nonrandomized study. *Circ Arrhythm Electrophysiol*. 2016;9.
 25. Gasparini M, Mantica M, Brignole M, et al. Long-term follow-up after atrioventricular nodal ablation and pacing: low incidence of sudden cardiac death. *Pacing Clin Electrophysiol: PACE*. 2000;23 Pt 2:1925–9.
 26. Jensen SM, Bergfeldt L, Rosenqvist M. Long-term follow-up of patients treated by radiofrequency ablation of the atrioventricular junction. *Pacing Clin Electrophysiol: PACE*. 1995;18 Pt 1:1609–14.
 27. Ozcan C, Jahangir A, Friedman PA, et al. Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction. *Am J Cardiol*. 2003;92:33–7.
 28. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. *N Engl J Med*. 2001;344:1043–51.
 29. Tan ES, Rienstra M, Wiesfeld AC, et al. Long-term outcome of the atrioventricular node ablation and pacemaker implantation for symptomatic refractory atrial fibrillation. *Europace*. 2008;10:412–8.
 30. Bjorkenheim A, Brandes A, Andersson T, et al. Predictors of hospitalization for heart failure and of all-cause mortality after atrioventricular nodal ablation and right ventricular pacing for atrial fibrillation. *Europace*. 2014;16:1772–8.
 31. Kim SG, Sompalli V, Rameneni A, et al. Symptomatic improvement after AV nodal ablation and pacemaker implantation for refractory atrial fibrillation and atrial flutter. *Angiology*. 1997;48:933–8.
 32. Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. *Europace*. 2012;14:1490–7.
 33. Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). *JACC Heart Fail*. 2013;1:500–7.
 34. Edner M, Caidahl K, Bergfeldt L, et al. Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. *Br Heart J*. 1995;74:261–7.
 35. Rodriguez LM, Smeets JL, Xie B, et al. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. *Am J Cardiol*. 1993;72:1137–41.
 36. Wood MA, Kay GN, Ellenbogen KA. The North American experience with the Ablate and Pace Trial (APT) for medically refractory atrial fibrillation. *Europace*. 1999;1:22–5.
 37. Szili-Torok T, Bountiukos M, Muskens AJ, et al. The presence of contractile reserve has no predictive value for the evolution of left ventricular function following atrio-ventricular node ablation in patients with permanent atrial fibrillation. *Eur J Echocardiogr*. 2005;6:344–50.
 38. Szili-Torok T, Kimman GP, Theuns D, et al. Deterioration of left ventricular function following atrio-ventricular node ablation and right ventricular apical pacing in patients with permanent atrial fibrillation. *Europace*. 2002;4:61–5.
 39. Tops LF, Schalij MJ, Holman ER, et al. Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. *J Am Coll Cardiol*. 2006;48:1642–8.
 40. Vernooy K, Dijkman B, Cheriex EC, et al. Ventricular remodeling during long-term right ventricular pacing following His bundle ablation. *Am J Cardiol*. 2006;97:1223–7.
 41. Lau DH, Thiyagarajah A, Willems S, et al. Device therapy for rate control: pacing resynchronisation and AV node ablation. *Heart Lung Circ*. 2017;26:934–40.
 42. Loring Z, Sun AY. Should his bundle pacing be preferred over cardiac resynchronization therapy following atrioventricular junction ablation? *Cardiol Clin*. 2019;37:231–40.
 43. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC) Developed in collaboration with the European Heart Rhythm Association (EHRA). *Eur Heart J*. 2013;34:2281–329.
 44. Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. *Eur Heart J*. 2011;32:2420–9.
 45. Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). *J Cardiovasc Electrophysiol*. 2005;16:1160–5.
 46. Brignole M, Pokushalov E, Pentimalli F, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. *Eur Heart J*. 2018;39:3999–4008.
 47. Gasparini M, Kloppe A, Lunati M, et al. Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations. *Eur J Heart Fail*. 2018;20:1472–81.
 48. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2016;18:891–975.

49. Abdelrahman M, Subzposh FA, Beer D, et al. Clinical outcomes of his bundle pacing compared to right ventricular pacing. *J Am Coll Cardiol.* 2018;71:2319–30.
50. Huang W, Su L, Wu S. Pacing treatment of atrial fibrillation patients with heart failure: his bundle pacing combined with atrioventricular node ablation. *Card Electrophysiol Clin.* 2018;10:519–35.
51. Huang W, Su L, Wu S, et al. Benefits of permanent his bundle pacing combined with atrioventricular node ablation in atrial fibrillation patients with heart failure with both preserved and reduced left ventricular ejection fraction. *J Am Heart Assoc.* 2017;6.
52. Occhetta E, Bortnik M, Magnani A, et al. Prevention of ventricular desynchronization by permanent para-Hisian pacing after atrioventricular node ablation in chronic atrial fibrillation: a crossover, blinded, randomized study versus apical right ventricular pacing. *J Am Coll Cardiol.* 2006;47:1938–45.
53. Sohinki D, Ho J, Srinivasan N, et al. Outcomes after atrioventricular node ablation and biventricular pacing in patients with refractory atrial fibrillation and heart failure: a comparison between non-ischaemic and ischaemic cardiomyopathy. *Europace.* 2014;16:880–6.
54. Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). *Eur Heart J.* 2019.
55. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. *J Am Coll Cardiol.* 2012;59:998–1005.